We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
Merck & Co. posted declines in sales and profit as the pharmaceutical giant gave revenue projections below analyst forecasts and earnings expectations on the lower end of them.
Shares, which have fallen 6% in the last three months, fell 2.8% in premarket trading.
Merck said it expects 2016 adjusted earnings per share of between $3.60 and $3.75 and revenue between $38.7 billion and $40.2 billion. Analysts polled by Thomson Reuters had expected earnings of $3.72 a share on revenue of $40.25 billion.
The quarter's pharmaceutical revenue fell 3.7% to $9.03 billion, including an 8% negative impact from currency fluctuations. Type 2 diabetes treatment Januvia posted a 12% sales decrease. Recently Januvia has faced an FDA safety alert about risk of joint pain for it and other drugs in its category. Merck said the decrease was expected and driven by the timing of purchases.
HPV vaccine Gardasil sales increased 40% due to an increase in government purchases in the U.S.
Sales of Remicade, a treatment for inflammatory diseases, decreased 29% due to loss of exclusivity and the accelerating impact of competition by biosimilar drugs.
In January, the U.S. Food and Drug Administration approved Merck's new treatment, Zepatier, for hepatitis C, the latest entrant in a booming market for drugs for the viral infection—a market now dominated by Gilead Sciences Inc.
Overall, the company posted a profit of $976 million, or 35 cents a share, down 87% from $7.32 billion, or $2.54 a share, a year prior.
The previous quarter's earnings included proceeds from the sale of Merck's over-the-counter business to Bayer AG for $14.2 billion. Excluding that and other items, earnings were 93 cents, up from 87 cents. Sales slipped 2.5% to $10.22 billion.
Analysts forecast per-share earnings of 91 cents a share on revenue of $10.35 billion.
Write to Austen Hufford at austen.hufford@wsj.com
(END) Dow Jones Newswires
February 03, 2016 08:15 ET (13:15 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions